New Strong Buy Stocks for November 15th
- FHI, RJF, ASTS, APLD and SPRO have been added to the Zacks Rank #1 (Strong Buy) List on November 15, 2024.
- 11/15/2024
|
Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Lags Revenue Estimates
- Spero Therapeutics, Inc. (SPRO) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to earnings of $0.02 per share a year ago.
- 11/14/2024
|
Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update
- Phase 3 PIVOT-PO trial of tebipenem HBr remains on track to complete enrollment in 2H 2025 Reiterate cash runway into mid-2026; Q3 2024 ending cash balance of $76.3M CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced financial results for the third quarter ended September 30, 2024, and provided a business update.
- 11/14/2024
|
Spero Therapeutics Announces Presentation of SPR719 (Active Moiety of SPR720) In Vitro Data Demonstrating Low Propensity for the Development of Resistance at IDWeek 2024
- In vitro data on SPR719 show low propensity for resistance development in NTM-PD MAC strains when administered as a single agent and in combination with standard of care agents
- 10/16/2024
|
Spero Therapeutics Announces Publication of SPR720 Phase 1 Lung Exposure Data in Antimicrobial Agents and Chemotherapy
- Phase 1 study showed significant lung uptake and enhanced epithelial lining fluid (ELF) and alveolar macrophage (AM) concentrations of SPR719 (active moiety of SPR720) Phase 1 study showed significant lung uptake and enhanced epithelial lining fluid (ELF) and alveolar macrophage (AM) concentrations of SPR719 (active moiety of SPR720)
- 10/02/2024
|
Spero Therapeutics, Inc. (SPRO) Q2 2024 Earnings Call Transcript
- Spero Therapeutics, Inc. (NASDAQ:SPRO ) Q2 2024 Earnings Conference Call August 5, 2024 4:30 AM ET Company Participants Shai Biran - Senior Director Investor Relations Sath Shukla - Chief Executive Officer Esther Rajavelu - CFO and Chief Business Officer Conference Call Participants Louise Chen - Cantor Fitzgerald Gavin Clark-Gartner - Evercore ISI Ritu Baral - TD Cowen Operator Good afternoon and welcome to the Spero Therapeutics Second Quarter 2024 Financial Results Conference Call. At this time all participants are in listen-only mode.
- 08/09/2024
|
Spero Therapeutics, Inc. (SPRO) Reports Q2 Loss, Tops Revenue Estimates
- Spero Therapeutics, Inc. (SPRO) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.23 per share a year ago.
- 08/05/2024
|
Spero Therapeutics Announces Second Quarter 2024 Operating Results and Provides a Business Update
- CAMBRIDGE, Mass., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced financial results for the second quarter ended June 30, 2024, and provided a business update.
- 08/05/2024
|
Spero Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on Monday, August 5, 2024
- CAMBRIDGE, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that management will host a conference call and live audio webcast on Monday August 5th, 2024 at 4:30 p.m. ET to report financial results for second quarter 2024 and provide an update on its business and pipeline.
- 07/29/2024
|
3 Micro-Cap Moonshots for Fearless Investors
- When discussing micro-cap stocks, it's important to recognize their general overlap with the world of penny stocks. These stocks trade as shares of companies with market capitalizations between $50 million and $300 million.
- 07/08/2024
|
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- CAMBRIDGE, Mass., July 03, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that on May 28, 2024, the Compensation Committee of Spero's Board of Directors approved the grant of an aggregate of 227,500 restricted stock unit awards (RSUs) to new employees under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, as amended (2019 Inducement Plan). The RSUs are being granted as an inducement material to each of the new employees becoming an employee of Spero in accordance with Nasdaq Listing Rule 5635(c)(4).
- 07/03/2024
|
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- CAMBRIDGE, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that on May 28, 2024, the Compensation Committee of Spero's Board of Directors approved the grant of 116,667 restricted stock unit awards (RSUs) to a new employee under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, as amended (2019 Inducement Plan). The RSUs are being granted as an inducement material to the new employee becoming an employee of Spero in accordance with Nasdaq Listing Rule 5635(c)(4).
- 06/03/2024
|
HC Wainwright Brokers Boost Earnings Estimates for Spero Therapeutics, Inc. (NASDAQ:SPRO)
- Spero Therapeutics, Inc. (NASDAQ:SPRO – Free Report) – HC Wainwright lifted their Q2 2024 EPS estimates for Spero Therapeutics in a note issued to investors on Thursday, May 16th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of ($0.25) for the quarter, up from their prior forecast of ($0.41). HC Wainwright currently has a “Buy” rating and a $7.00 target price on the stock. The consensus estimate for Spero Therapeutics’ current full-year earnings is ($1.04) per share. HC Wainwright also issued estimates for Spero Therapeutics’ Q3 2024 earnings at ($0.27) EPS, Q4 2024 earnings at ($0.26) EPS, FY2024 earnings at ($1.01) EPS and FY2025 earnings at ($0.87) EPS. Spero Therapeutics (NASDAQ:SPRO – Get Free Report) last posted its quarterly earnings data on Wednesday, March 13th. The company reported $0.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.18) by $1.14. The company had revenue of $73.52 million for the quarter, compared to analyst estimates of $19.40 million. Spero Therapeutics had a net margin of 21.09% and a return on equity of 35.42%. Separately, Cantor Fitzgerald reiterated an “overweight” rating on shares of Spero Therapeutics in a research note on Thursday, April 4th. Read Our Latest Research Report on SPRO Spero Therapeutics Stock Up 1.3 % SPRO opened at $1.59 on Monday. The firm has a market capitalization of $85.84 million, a P/E ratio of 3.70 and a beta of 0.62. The firm’s 50 day moving average is $1.63 and its 200-day moving average is $1.48. Spero Therapeutics has a 52-week low of $0.99 and a 52-week high of $1.94. Institutional Trading of Spero Therapeutics A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Murchinson Ltd. increased its stake in shares of Spero Therapeutics by 1.3% in the first quarter. Murchinson Ltd. now owns 873,910 shares of the company’s stock worth $1,503,000 after buying an additional 11,210 shares during the last quarter. Acadian Asset Management LLC increased its stake in shares of Spero Therapeutics by 121.8% in the first quarter. Acadian Asset Management LLC now owns 762,598 shares of the company’s stock worth $1,310,000 after buying an additional 418,742 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Spero Therapeutics by 0.6% in the first quarter. Vanguard Group Inc. now owns 1,653,432 shares of the company’s stock worth $2,844,000 after buying an additional 9,675 shares during the last quarter. Finally, ADAR1 Capital Management LLC bought a new stake in shares of Spero Therapeutics in the fourth quarter worth $1,570,000. Institutional investors own 25.60% of the company’s stock. Spero Therapeutics Company Profile (Get Free Report) Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. Read More Five stocks we like better than Spero Therapeutics How to Effectively Use the MarketBeat Ratings Screener MarketBeat Week in Review – 5/13 – 5/17 3 Ways To Invest In Coffee, Other Than Drinking It Take-Two Interactive Software Offers 2nd Chance for Investors How to Know if a Stock Pays Dividends and When They Are Paid Out Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook
- 05/20/2024
|
Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference
- CAMBRIDGE, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Sath Shukla, President and Chief Executive Officer of Spero Therapeutics, will participate in a fireside chat and be available for one-on-one meetings at the H.C. Wainwright 2 nd Annual BioConnect Investor Conference at NASDAQ, to take place on Monday, May 20, 2024, at the NASDAQ World Headquarters New York, NY. Details are as follows:
- 05/16/2024
|
Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update
- CAMBRIDGE, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced financial and operational results for the quarter ended March 31, 2024.
- 05/15/2024
|
Spero Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on Wednesday, May 15, 2024
- CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will report its first quarter 2024 financial results and provide an update on its business and pipeline on Wednesday, May 15, after the market close. The Company does not intend to host a conference call, and anticipates resuming quarterly earnings calls at the time it announces second quarter 2024 results.
- 05/08/2024
|
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- CAMBRIDGE, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that on April 29, 2024, the Compensation Committee of Spero's Board of Directors approved the grant of an aggregate of 10,833 restricted stock unit awards (RSUs) to a new employee under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, as amended, or the 2019 Inducement Plan. The RSUs are being granted as inducements material to the new employee, becoming an employee of Spero in accordance with Nasdaq Listing Rule 5635(c)(4).
- 05/01/2024
|
Spero Therapeutics Delivers On Game Plan To Create Shareholder Value
- Spero Therapeutics, Inc. has continued to build and advance its pipeline over the past several months and is now on the verge of generating landmark data with multi-bagger potential. Spero has excellent downside protection and additional upside from the payments from the Tebipenem HBr deal with GSK. Spero's significant undervaluation and potential path forward are highlighted in the peer comparison.
- 04/23/2024
|
Spero Therapeutics, Inc. (SPRO) Q4 Earnings and Revenues Top Estimates
- Spero Therapeutics, Inc. (SPRO) came out with quarterly earnings of $0.96 per share, beating the Zacks Consensus Estimate of a loss of $0.18 per share. This compares to earnings of $0.55 per share a year ago.
- 03/13/2024
|
Spero Therapeutics, Inc. (SPRO) Q4 2023 Earnings Call Transcript
- Spero Therapeutics, Inc. (SPRO) Q4 2023 Earnings Call Transcript
- 03/13/2024
|
Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business Update
- CAMBRIDGE, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.
- 03/13/2024
|
Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024
- CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will host a conference call and live audio webcast on Wednesday, March 13, 2024 at 4:30 p.m. ET to report its fourth quarter and full year financial results and provide an update on its business and pipeline.
- 03/06/2024
|
Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infections
- CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it has received clearance by the U.S. Food and Drug Administration (FDA) for its investigational new drug (IND) application, to evaluate SPR206 in a Phase 2 clinical study. SPR206 is a novel, intravenously (IV) administered next-generation polymyxin antibiotic for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by MDR Gram-negative bacterial infections.
- 02/28/2024
|
Spero Therapeutics to Present at Cowen's 44th Annual Healthcare Conference
- CAMBRIDGE, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel therapies for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Sath Shukla, President and Chief Executive Officer of Spero Therapeutics, will present and be available for one-on-one meetings at the Cowen 44th Annual Healthcare Conference, which is taking place March 4-6, 2024, at the Boston Marriott Copley Place in Boston, MA. Details are as follows:
- 02/26/2024
|
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that on January 29, 2024, the Compensation Committee of Spero's Board of Directors approved the grant of an aggregate of 50,000 restricted stock unit awards (RSUs) to a new employee under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, as amended, or the 2019 Inducement Plan. The RSUs are being granted as inducements material to the new employee becoming an employee of Spero in accordance with Nasdaq Listing Rule5635(c)(4).
- 01/31/2024
|
Spero Therapeutics Provides Corporate Update and 2024 Outlook
- In 2H 2024, expect to provide Phase 2a topline proof-of-concept data from our wholly-owned lead program SPR720 in NTM-PD patients
- 01/05/2024
|
Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections
- $95 million in development milestones payable over two years, as part of GSK license agreement $95 million in development milestones payable over two years, as part of GSK license agreement
- 01/02/2024
|
Spero Therapeutics, Inc. (SPRO) Q3 2023 Earnings Call Transcript
- Spero Therapeutics, Inc. (NASDAQ:SPRO ) Q3 2023 Earnings Conference Call November 13, 2023 4:30 PM ET Company Participants Ted Jenkins - Vice President, Investor Relations and Strategic Finance Sath Shukla - Chief Executive Officer Kamal Hamed - Chief Medical Officer Steve Dipalma - Interim Chief Financial Officer and Treasurer Conference Call Participants Louise Chen - Cantor Fitzgerald Boobalan Pachaiyappan - H.C. Wainwright Good afternoon and welcome to the Spero Therapeutics Third Quarter 2023 Financial Results Conference Call.
- 11/13/2023
|
Spero Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on Monday, November 13, 2023
- CAMBRIDGE, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will host a conference call and live audio webcast on Monday, November 13, 2023 at 4:30 p.m. ET to report its third quarter 2023 financial results and provide an update on its business and pipeline.
- 11/06/2023
|
SPERO ALERT: Bragar Eagel & Squire, P.C. is Investigating Spero Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
- NEW YORK--(BUSINESS WIRE)-- #A--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Spero Therapeutics, Inc. (NASDAQ: SPRO) on behalf of long-term stockholders following a class action complaint that was filed against Spero with a Class Period from October 28, 2021 to May 2, 2022. Our investigation concerns whether the board of directors of Spero have breached their fiduciary duties to the company. Spero, a clinical-stage bi.
- 11/02/2023
|
Spero Therapeutics Appoints Esther Rajavelu as Chief Financial Officer and Chief Business Officer
- Ms. Rajavelu brings over two decades of experience in the life sciences sector focused on strategic growth, financing, M&A, and investor relations. Ms. Rajavelu brings over two decades of experience in the life sciences sector focused on strategic growth, financing, M&A, and investor relations.
- 11/01/2023
|
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that on October 27, 2023, the Compensation Committee of Spero's Board of Directors approved the grant of an aggregate of 65,000 restricted stock unit awards (RSUs) to a new employee under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, as amended, or the 2019 Inducement Plan. The RSUs are being granted as inducements material to the new employee, becoming an employee of Spero in accordance with Nasdaq Listing Rule5635(c)(4).
- 10/31/2023
|
All You Need to Know About Spero Therapeutics, Inc. (SPRO) Rating Upgrade to Buy
- Spero Therapeutics, Inc. (SPRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 10/18/2023
|
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Spero Therapeutics, Inc. (NASDAQ: SPRO) for Potential Breaches of Fiduciary Duty By Its Board of Directors
- NEW YORK , Oct. 11, 2023 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Spero Therapeutics, Inc. (NASDAQ: SPRO). If you are a shareholder of Spero Therapeutics, Inc. and want to receive additional information and protect your investments free of charge, please visit us at: https://pjlfirm.com/spero-therapeutics-inc/ You may also contact Robert H.
- 10/11/2023
|
Spero Therapeutics to Present at Cantor's Global Healthcare 2023 Investor Conference
- CAMBRIDGE, Mass., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Sath Shukla, President and Chief Executive Officer of Spero Therapeutics, will present and be available for one-on-one meetings at Cantor Fitzgerald's Global Healthcare 2023 Investor Conference, which will be held on September 26-28, 2023, at the Intercontinental Barclay Hotel in New York, NY. Details are as follows:
- 09/20/2023
|
Spero Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference
- CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Sath Shukla, President and Chief Executive Officer of Spero Therapeutics, will present and be available for one-on-one meetings at the H.C. Wainwright 25th Annual Global Investment Conference, which is taking place September 11-13, 2023, at the Lotte New York Palace Hotel in New York, NY. Details are as follows:
- 09/06/2023
|
Spero Therapeutics, Inc. (SPRO) Upgraded to Strong Buy: What Does It Mean for the Stock?
- Spero Therapeutics, Inc. (SPRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
- 08/29/2023
|
New Strong Buy Stocks for August 29th
- SPRO, FBIZ, KNSL, BMI and FDUS have been added to the Zacks Rank #1 (Strong Buy) List on August 29, 2023.
- 08/29/2023
|
Down -11.72% in 4 Weeks, Here's Why Spero Therapeutics, Inc. (SPRO) Looks Ripe for a Turnaround
- The heavy selling pressure might have exhausted for Spero Therapeutics, Inc. (SPRO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
- 08/22/2023
|
Spero Therapeutics, Inc. (SPRO) Reports Q2 Loss, Tops Revenue Estimates
- Spero Therapeutics, Inc. (SPRO) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.87 per share a year ago.
- 08/10/2023
|
Spero Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023
- CAMBRIDGE, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will host a conference call and live audio webcast on Thursday, August 10, 2023 at 4:30 p.m. ET to report its second quarter 2023 financial results and provide an update on its business and pipeline.
- 08/03/2023
|
Spero Therapeutics shares rise on FDA approval of pivotal complicated UTI trial
- Spero Therapeutics shares soared after the clinical-stage biopharmaceutical company announced that it has received special protocol approval from the United States Food and Drug Administration (FDA) for the design and size of its Phase 3 study of its investigational therapeutic tebipenem HBr in patients with complicated urinary tract infection (cUTI), including acute pyelonephritis (AP). Shares of the Cambridge, Massachusetts-based company, which is focused on developing and commercializing treatments for rare diseases and multi-drug resistant bacterial infections, had added 14.1% at US$1.62 on Monday afternoon.
- 07/31/2023
|
Spero Therapeutics: The Multi-Asset Pipeline Could Outpace The Tebipenem HBr Deal With GSK
- Spero is eligible to receive up to $525 million in development and sales milestone payments as well as royalties on net product sales under the agreement with GSK. In addition, Spero has two other assets that will soon be evaluated in proof-of-concept studies, both of which address significant unmet medical needs and have high commercial potential. The lead compound, SPR720, could be approved under an accelerated approval pathway and offers potential blockbuster status with peak sales of up to $1 billion.
- 07/05/2023
|
Spero Therapeutics, Inc. (SPRO) Q1 2023 Earnings Call Transcript
- Spero Therapeutics, Inc. (NASDAQ:SPRO ) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Ted Jenkins – Vice President, Investor Relations and Strategic Finance Ankit Mahadevia – Chief Executive Officer Sath Shukla – Chief financial Officer Kamal Hamed – Chief Medical Officer Conference Call Participants Louise Chen – Cantor Ritu Baral – TD Cowen Gavin Clark-Gartner – Evercore ISI Boobalan Pachaiyappan – H.C. Wainwright Operator Good afternoon, and welcome to the Spero Therapeutics First Quarter 2023 Financial Results Conference Call.
- 05/11/2023
|
Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Tops Revenue Estimates
- Spero Therapeutics, Inc. (SPRO) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $1.01 per share a year ago.
- 05/11/2023
|
Spero Therapeutics to Provide Business Update and Report First Quarter 2023 Financial Results on Thursday, May 11, 2023
- CAMBRIDGE, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will host a conference call and live audio webcast on Thursday, May 11, 2023 at 4:30 p.m. ET to report its first quarter 2023 financial results and provide an update on its business and pipeline.
- 05/04/2023
|
Spero Therapeutics to Present at Upcoming Investor Conference
- CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Spero's management team will present and be available for one-on-one meetings at the H.C. Wainwright BioConnect Investor Conference at NASDAQ in New York City, on May 2, 2023. Details are as follows:
- 04/26/2023
|
Spero Therapeutics: Massive Partnership Deal Still Not Properly Valued By The Market
- Spero Therapeutics: Massive Partnership Deal Still Not Properly Valued By The Market.
- 04/21/2023
|
Spero Therapeutics to Present Data at the 33rd European Congress of Clinical Microbiology and Infectious Diseases
- CAMBRIDGE, Mass., April 14, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced two poster presentations at the 33r d European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) being held April 15-18, 2023, in Copenhagen, Denmark.
- 04/14/2023
|
Spero Therapeutics, Inc. (SPRO) Q4 2022 Earnings Call Transcript
- Spero Therapeutics, Inc. (NASDAQ:SPRO ) Q4 2022 Earnings Conference Call March 30, 2023 4:30 PM ET Company Participants Ted Jenkins - VP & Head, IR Ankit Mahadevia - Co-Founder, President, CEO & Director Kamal Hamed - Chief Medical Officer Satyavrat Shukla - CFO & Treasurer Conference Call Participants Louise Chen - Cantor Fitzgerald & Co. Operator Good afternoon, and welcome to Spero Therapeutics Fourth Quarter and Year-End 2022 Financial Results Conference Call. [Operator Instructions].
- 03/30/2023
|
Spero Therapeutics, Inc. (SPRO) Q4 Earnings and Revenues Beat Estimates
- Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 237.50% and 2,865.06%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 03/30/2023
|
Spero Therapeutics Reschedules Fourth Quarter and Full Year 2022 Earnings Release and Conference Call to March 30, 2023
- CAMBRIDGE, Mass., March 13, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas, involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it has changed the date of its previously announced 2022 fourth quarter and full year earnings release and conference call from today, Monday, March 13, 2023 to Thursday, March 30, 2023. Spero is still evaluating the accounting treatment associated with the GSK transaction in 2022 and needs additional time to complete its audit and file its Annual Report on Form 10-K for the fiscal year ended December 31, 2022.
- 03/13/2023
|
Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results on Monday, March 13, 2023
- CAMBRIDGE, Mass., March 06, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas, involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will host a conference call and live audio webcast on Monday, March 13, 2023 at 4:30 p.m. ET to report its fourth quarter and full year financial results and provide an update on its business and pipeline.
- 03/06/2023
|
Spero Therapeutics to Present at Upcoming Investor Conferences
- CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will present and be available for one-on-one meetings at the Cowen 43rd Annual Healthcare Conference, which is taking place March 6-8, 2023, at the Boston Marriott Copley Place in Boston, MA, and Oppenheimer's 33rd Annual Healthcare Conference, which is taking place virtually, March 13-15, 2023. Details are as follows:
- 02/28/2023
|
Down -12.5% in 4 Weeks, Here's Why Spero Therapeutics, Inc. (SPRO) Looks Ripe for a Turnaround
- Spero Therapeutics, Inc. (SPRO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
- 02/23/2023
|
Spero Therapeutics, Inc. (SPRO) Loses -9.78% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
- Spero Therapeutics, Inc. (SPRO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
- 02/22/2023
|
Spero Therapeutics to Present at the 5th Annual Evercore ISI HealthCONx Conference
- CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will participate in a fireside chat and be available for one-on-one meetings at the 5th Annual Evercore ISI HealthCONx Conference, which is taking place virtually, November 29, 2022 through December 1, 2022. Details for the fireside chat are as follows:
- 11/22/2022
|
Spero Therapeutics, Inc. (SPRO) Q3 2022 Earnings Call Transcript
- Spero Therapeutics, Inc. (NASDAQ:SPRO ) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Ted Jenkins - Vice President, Investor Relations & Strategic Finance Ankit Mahadevia - Chief Executive Officer Kamal Hamed - Chief Medical Officer Sat Shukla - Chief Financial Officer Conference Call Participants Gavin Clark-Gartner - Evercore ISI Louise Chen - Cantor Ritu Baral - Cowen Operator Good afternoon and welcome to the Spero Therapeutics' Third Quarter 2022 Financial Results Conference Call. At this time, all participants are in listen-only mode.
- 11/14/2022
|
Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Misses Revenue Estimates
- Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 2.94% and 70.28%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- 11/14/2022
|
Spero Therapeutics to Provide Business Update and Report Third Quarter 2022 Financial Results on Monday, November 14, 2022
- CAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will host a conference call and live audio webcast on Monday, November 14, 2022 at 4:30 p.m. ET to report its third quarter 2022 financial results and provide an update on its business and pipeline.
- 11/07/2022
|
Spero Therapeutics to Present Data at IDWeek 2022
- CAMBRIDGE, Mass., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced data presentations for 7 abstracts accepted at the Infectious Disease Society of America (IDSA) IDWeek™ 2022, taking place from October 19 – 23, 2022 in Washington, DC.
- 10/19/2022
|
These Were The Five Best And Worst Performing Healthcare Stocks In September 2022
- September was another lackluster month for the stock market, with the S&P 500 dropping by over 9%.
- 10/17/2022
|
Spero Therapeutics: The GlaxoSmithKline-Deal Changes Everything And Protects Shareholder Value
- Following the breakthrough deal with GlaxoSmithKline, Spero is in a comfortable position to advance its pipeline. The $150 million non-performance related milestone payment, equivalent to $3.2 per share, associated with Phase 3 clinical trial provides sufficient upside from today's share price.
- 10/03/2022
|
Cheap Stocks To Buy Now? Hot Penny Stocks To Watch In October
- Hot penny stocks to watch for October. The post Cheap Stocks To Buy Now?
- 09/30/2022
|
Hot Penny Stocks To Watch As The Stock Market Crash Continues
- Hot penny stocks to add to your watch list this week. Is it time to buy?
- 09/26/2022
|
Spero (SPRO) Skyrockets 168% on Licensing Deal With GSK
- The exclusive licensing agreement with GSK will fund Spero's (SPRO) existing operations and extend its current cash runway beyond 2024.
- 09/23/2022
|
Reddit Penny Stocks to Watch as September Ends
- Check these Reddit penny stocks out for your watchlist right now The post Reddit Penny Stocks to Watch as September Ends appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 09/23/2022
|
Spero's stock jumps 188% after GSK licenses experimental antibiotic
- Shares of Spero Therapeutics Inc. SPRO, +277.39% soared 188.4% in trading on Thursday morning after the company signed an exclusive license agreement with GlaxoSmithKline GSK, -0.32% for its experimental antibiotic for complicated urinary tract infections. Spero's therapy, tebipenem HBr, is expected to enter Phase 3 clinical trials next year.
- 09/22/2022
|
Spero Therapeutics (SPRO) Soars 137% on Exclusive License Agreement
- Source: Willy Barton / Shutterstock.com Spero Therapeutics (NASDAQ: SPRO ) stock is rocketing higher on Thursday after the company signed a licensing agreement with GSK (NYSE: GSK ). This deal covers the rights to tebipenem HBr, which is an antibiotic asset in late-stage development by Spero Therapeutics.
- 09/22/2022
|
Looking for Popular Penny Stocks to Buy? 3 to Watch Now
- Which penny stocks are you buying today? The post Looking for Popular Penny Stocks to Buy?
- 09/08/2022
|
Spero (SPRO) Up Following Positive FDA Update for UTI Drug
- Spero (SPRO) surges on achieving common ground with the FDA on the regulatory path forward for tebipenem HBr.
- 09/07/2022
|
Why Is Spero Therapeutics (SPRO) Stock Up 15% Today?
- Source: Shutterstock Spero Therapeutics (NASDAQ: SPRO ) stock is climbing higher on Wednesday thanks to positive feedback from the FDA. That concerns plans to resubmit tebipenem HBr for the treatment of complicated urinary tract infection (cUTI).
- 09/07/2022
|
Spero Therapeutics to Present at Upcoming Investor Conference
- CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will present and be available for one-on-one meetings at the 24th Annual H.C. Wainwright Global Investment Conference, which is taking place September 12-14, 2022. Details for the presentation are as follows:
- 09/07/2022
|
Are These Penny Stocks on Your September Buy List?
- Here's what you need to know about buying penny stocks on September 7th The post Are These Penny Stocks on Your September Buy List? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 09/07/2022
|
Spero Therapeutics, Inc. (SPRO) CEO Ankit Mahadevia on Q2 2022 Results - Earnings Call Transcript
- Spero Therapeutics, Inc. (NASDAQ:SPRO ) Q2 2022 Earnings Conference Call August 10, 2022 4:30 PM ET Company Participants Ted Jenkins - Vice President-Investor Relations & Strategic Finance Ankit Mahadevia - Chief Executive Officer David Melnick - Consultant & Senior Clinical Advisor Sath Shukla - Chief Financial Officer Conference Call Participants Ritu Baral - Cowen Louise Chen - Cantor Boobalan Pachaiyappan - H.C. Wainwright Operator Good afternoon, and welcome to the Spero Therapeutics Second Quarter 2022 Financial Results Conference Call.
- 08/11/2022
|
Spero Therapeutics, Inc. (SPRO) Reports Q2 Loss, Misses Revenue Estimates
- Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 1.14% and 13.35%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- 08/10/2022
|
Spero Therapeutics to Provide Business Update and Report Second Quarter 2022 Financial Results on Wednesday, August 10, 2022
- CAMBRIDGE, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced that it will host a conference call and live audio webcast on Wednesday, August 10, 2022 at 4:30 p.m. ET to report its second quarter 2022 financial results and provide an update on its business and pipeline.
- 08/09/2022
|
Spero Therapeutics, Inc. (SPRO) CEO Ankit Mahadevia on Q1 2022 Results - Earnings Call Transcript
- Spero Therapeutics, Inc. (NASDAQ:SPRO ) Q1 2022 Earnings Conference Call May 16, 2022 4:30 PM ET Company Participants Ted Jenkins - Vice President-Investor Relations Ankit Mahadevia - Chief Executive Officer David Melnick - Chief Medical Officer Sath Shukla - Chief Financial Officer Conference Call Participants Louise Chen - Cantor Ram Selvaraju - H.C. Wainwright Kevin DeGeeter - Oppenheimer Elaine Kim - Berenberg Operator Good afternoon, and welcome to the Spero Therapeutics First Quarter of 2022 Financial Results Conference Call.
- 05/16/2022
|
Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Lags Revenue Estimates
- Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of -16.09% and 27.40%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- 05/16/2022
|
Spero Therapeutics to Present at Upcoming Investor Conferences
- CAMBRIDGE, Mass., May 11, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections and rare diseases, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will present and be available for one-on-one meetings at the 2022 RBC Capital Markets Global Healthcare Conference and the H.C. Wainwright Global Investment Conference, which are taking place May 17-18 and May 23-25, respectively. Details for the presentations are as follows:
- 05/11/2022
|
Spero Therapeutics to Provide Business Update and Report First Quarter 2022 Financial Results on Monday, May 16, 2022
- CAMBRIDGE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced that it will host a conference call and live audio webcast on Monday, May 16, 2022, at 4:30 p.m. ET to report its first quarter 2022 financial results and provide an update on its business and pipeline.
- 05/09/2022
|
SPRO Stock Alert: 9 Things to Know as Spero Therapeutics Plunges 50%
- Spero Therapeutics (SPRO) stock is taking a beating on Tuesday after the biotech company revealed a change in strategic direction. The post SPRO Stock Alert: 9 Things to Know as Spero Therapeutics Plunges 50% appeared first on InvestorPlace.
- 05/03/2022
|
Spero Therapeutics to Present Data at the 32nd European Congress of Clinical Microbiology and Infectious Diseases
- CAMBRIDGE, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced two oral presentations and four poster presentations at the 32nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) being held April 23-26, 2022, in Lisbon, Portugal.
- 04/21/2022
|
Spero Therapeutics, Inc. (SPRO) CEO Ankit Mahadevia on Q4 2021 Results - Earnings Call Transcript
- Spero Therapeutics, Inc. (SPRO) CEO Ankit Mahadevia on Q4 2021 Results - Earnings Call Transcript
- 03/31/2022
|
Spero Therapeutics, Inc. (SPRO) Reports Q4 Loss, Lags Revenue Estimates
- Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of -12.50% and 5.38%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
- 03/31/2022
|
Is a Surprise Coming for Spero Therapeutics (SPRO) This Earnings Season?
- Spero Therapeutics (SPRO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 03/29/2022
|
Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full-Year 2021 Financial Results on Thursday, March 31, 2022
- CAMBRIDGE, Mass., March 17, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), today announced that it will host a conference call and live audio webcast on Thursday, March 31, 2022, at 4:30 p.m. ET to report its fourth quarter and full-year 2021 financial results and provide an update on its business and pipeline.
- 03/17/2022
|
FDA Lifts Clinical Hold On Spero Therapeutics' Lung Infection Program
- The FDA has lifted the clinical hold on Spero Therapeutics Inc's (NASDAQ: SPRO) Phase 2 trial of SPR720 for nontuberculous mycobacterial (NTM) disease. The SPR720 program was placed on a clinical hold by the FDA following a review of data from a non-human primate (NHP) toxicology study in which mortalities with inconclusive causality to treatment were observed.
- 01/04/2022
|
Spero (SPRO) Application for UTI Drug Gets Priority Review
- Spero's (SPRO) NDA for tebipenem HBr oral tablets for complicated urinary tract infections gets Priority Review.
- 01/04/2022
|
Spero Therapeutics to Present at Upcoming Investor Conferences
- CAMBRIDGE, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will present and be available for one-on-one meetings at the Piper Sandler 33rd Annual Virtual Healthcare Conference and the 4th Annual Evercore ISI HealthCONx Conference, which are taking place virtually, November 29, 2021 through December 2, 2021 and November 30, 2021 through December 2, 2021, respectively. Details for the presentations are as follows.
- 11/17/2021
|
Spero Therapeutics, Inc. (SPRO) CEO Ankit Mahadevia on Q3 2021 Results - Earnings Call Transcript
- Spero Therapeutics, Inc. (SPRO) CEO Ankit Mahadevia on Q3 2021 Results - Earnings Call Transcript
- 11/10/2021
|
Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Tops Revenue Estimates
- Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 0.00% and 2.13%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
- 11/10/2021
|
Spero Therapeutics to Provide Business Update and Report Third Quarter 2021 Financial Results on Wednesday, November 10, 2021
- CAMBRIDGE, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that it will host a conference call and live audio webcast on Wednesday, November 10, 2021, at 4:30 p.m. ET to report its third quarter 2021 financial results and provide an update on its business and pipeline.
- 11/03/2021
|
Spero Therapeutics, Inc. (SPRO) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
- Spero Therapeutics, Inc. (SPRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 10/28/2021
|
Spero Therapeutics Appoints Kathleen Tregoning to its Board of Directors
- Ms. Tregoning brings more than two decades of experience in biotechnology and public policy to Spero's Board Ms. Tregoning brings more than two decades of experience in biotechnology and public policy to Spero's Board
- 10/12/2021
|
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- CAMBRIDGE, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that on September 30, 2021, the Compensation Committee of Spero's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 12,900 shares of its common stock to three new employees under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, or the 2019 Inducement Plan. The stock options were granted as inducements material to the new employees becoming employees of Spero in accordance with Nasdaq Listing Rule 5635(c)(4).
- 10/01/2021
|
Spero Therapeutics Inks Revenue Interest Financing Agreement With HealthCare Royalty Partners
- Spero Therapeutics Inc (NASDAQ: SPRO) has entered into a revenue interest financing agreement with HealthCare Royalty Partners for up to $125 million. Spero will use the proceeds to prepare for the anticipated launch of tebipenem HBr and support the continued clinical development of SPR720 and SPR206.
- 09/30/2021
|
Spero Therapeutics Enters Into a Non-Dilutive Revenue Interest Financing Agreement With HealthCare Royalty Partners® for Up to $125 Million
- Investment expected to extend Spero Therapeutics' cash runway into 2H 2023 Investment expected to extend Spero Therapeutics' cash runway into 2H 2023
- 09/30/2021
|
Spero Therapeutics to Present Data at IDWeek 2021
- CAMBRIDGE, Mass., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced 23 data presentations at the Infectious Disease Society of America (IDSA) IDWeekTM 2021, taking place virtually from September 29 – October 3, 2021. Presentations will showcase in vitro and in vivo studies of Spero's oral antibiotic investigational candidate tebipenem HBr for the treatment of adults with complicated urinary tract infection (cUTI) and acute pyelonephritis (AP) and highlight additional research on the epidemiology and management of cUTI.
- 09/16/2021
|
Spero Therapeutics to Present at Three Upcoming Investor Conferences
- CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will present and be available for virtual one-on-one meetings at the H.C. Wainwright 23rd Annual Global Investment Conference, the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit, and the 2021 Cantor Virtual Global Healthcare Conference, taking place virtually September 13 – 15th, 2021, September 20 – 23rd, 2021, and September 27 – 30th, 2021, respectively.
- 09/07/2021
|
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- CAMBRIDGE, Mass., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that on August 31, 2021, the Compensation Committee of Spero's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 98,300 shares of its common stock to 7 new employees under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, or the 2019 Inducement Plan. The stock options were granted as inducements material to the new employees becoming employees of Spero in accordance with Nasdaq Listing Rule 5635(c)(4).
- 08/31/2021
|
Here's Why Momentum Investors Will Love Spero Therapeutics, Inc. (SPRO)
- Does Spero Therapeutics, Inc. (SPRO) have what it takes to be a top stock pick for momentum investors? Let's find out.
- 08/31/2021
|
Spero Therapeutics, Inc. (SPRO) CEO Ankit Mahadevia on Q2 2021 Results - Earnings Call Transcript
- Spero Therapeutics, Inc. (SPRO) CEO Ankit Mahadevia on Q2 2021 Results - Earnings Call Transcript
- 08/07/2021
|
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- CAMBRIDGE, Mass., July 30, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that on July 30, 2021, the Compensation Committee of Spero's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 114,600 shares of its common stock to ten new employees under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, or the 2019 Inducement Plan. The stock options were granted as inducements material to the new employees becoming employees of Spero in accordance with Nasdaq Listing Rule 5635(c)(4).
- 07/30/2021
|
Spero Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference
- CAMBRIDGE, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will give a corporate presentation and be available for virtual one-on-one meetings at the Ladenburg Thalmann Healthcare Conference, taking place virtually from July 13 – 14, 2021. Details for the presentation are as follows:
- 07/07/2021
|
DuPont De Nemours, Inc Among Today's Trending Stocks
- Q.ai runs daily factor models to get the most up-to-date reading on stocks and ETFs. Today, our deep-learning algorithms have identified DuPont De Nemours, Inc among others.
- 07/06/2021
|
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- CAMBRIDGE, Mass., July 02, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that on June 30, 2021, the Compensation Committee of Spero's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 85,650 shares of its common stock to nine new employees under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, or the 2019 Inducement Plan. The stock options were granted as inducements material to the new employees becoming employees of Spero in accordance with Nasdaq Listing Rule 5635(c)(4).
- 07/02/2021
|
Why Spero Therapeutics Stock Is Up 15% Today
- The small biopharma's work has captured the attention of a much bigger player.
- 07/01/2021
|
SPRO Stock Price Increases Over 25% Pre-Market: Why It Happened
- The stock price of Spero Therapeutics, Inc. (Nasdaq: SPRO) increased by over 25% pre-market. This is why it happened.
- 07/01/2021
|
Spero Therapeutics Announces $40 Million Equity Investment from Pfizer Inc. and Licensing Agreement for SPR206
- Spero grants Pfizer rights to develop, manufacture, and commercialize SPR206 in ex-U.S. and ex-Asia territories in exchange for potential development and commercial milestone payments and royalties. Spero grants Pfizer rights to develop, manufacture, and commercialize SPR206 in ex-U.S. and ex-Asia territories in exchange for potential development and commercial milestone payments and royalties.
- 06/30/2021
|
Spero Therapeutics Announces the Initiation of Bronchoalveolar Lavage and Renal Impairment Clinical Trials of SPR206
- CAMBRIDGE, Mass., June 15, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced the initiation of two Phase 1 trials of SPR206, an intravenously (IV)-administered next-generation polymyxin product candidate. SPR206 was derived from Spero's potentiator platform and is being developed to treat serious multi-drug resistant (MDR) Gram-negative infections in the hospital setting. These trials, which are now open for enrollment, include a bronchoalveolar lavage (BAL) clinical trial assessing the penetration of SPR206 into the pulmonary compartment and a renal impairment clinical trial.
- 06/15/2021
|
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- CAMBRIDGE, Mass., May 28, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that on May 28, 2021, the Compensation Committee of Spero's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 36,000 shares of its common stock to seven new employees under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, or the 2019 Inducement Plan. The stock options were granted as inducements material to the new employees becoming employees of Spero in accordance with Nasdaq Listing Rule 5635(c)(4).
- 05/28/2021
|
Spero Therapeutics, Inc. (SPRO) CEO Ankit Mahadevia on Q1 2021 Results - Earnings Call Transcript
- Spero Therapeutics, Inc. (SPRO) CEO Ankit Mahadevia on Q1 2021 Results - Earnings Call Transcript
- 05/09/2021
|
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- CAMBRIDGE, Mass., April 30, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that on April 30, 2021, the Compensation Committee of Spero's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 28,600 shares of its common stock to three new employees under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, or the 2019 Inducement Plan. The stock options were granted as inducements material to the new employees becoming employees of Spero in accordance with Nasdaq Listing Rule 5635(c)(4).
- 04/30/2021
|
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- CAMBRIDGE, Mass., March 31, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that on March 31, 2021 the Compensation Committee of Spero's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 22,050 shares of its common stock to three new employees under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, or the 2019 Inducement Plan. The stock options were granted as inducements material to the new employees becoming employees of Spero in accordance with Nasdaq Listing Rule 5635(c)(4).
- 03/31/2021
|
Spero Therapeutics' (SPRO) CEO Ankit Mahadevia on Q4 2020 Results - Earnings Call Transcript
- Spero Therapeutics' (SPRO) CEO Ankit Mahadevia on Q4 2020 Results - Earnings Call Transcript
- 03/11/2021
|
Spero Therapeutics, Inc. (SPRO) Reports Q4 Loss, Lags Revenue Estimates
- Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 11.69% and -41.32%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
- 03/11/2021
|
Spero Therapeutics Announces Fourth Quarter and Full-Year 2020 Operating Results and Provides Business Update
- Tebipenem HBr advancing towards NDA submission in the second half of 2021
- 03/11/2021
|
Will Spero Therapeutics, Inc. (SPRO) Report Negative Q4 Earnings? What You Should Know
- Spero Therapeutics, Inc. (SPRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 03/08/2021
|
Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full-Year 2020 Financial Results on Thursday, March 11, 2021
- CAMBRIDGE, Mass., March 03, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that it will host a conference call and live audio webcast on March 11, 2021 at 4:30 p.m. EST to report its fourth quarter and full-year 2020 financial results and provide an update on its business and pipeline.
- 03/03/2021
|
Spero Therapeutics Provides Update on SPR720 Phase 2a Clinical Trial
- CAMBRIDGE, Mass., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that the United States Food and Drug Administration (FDA) informed Spero that a clinical hold has been placed on its Phase 2a clinical trial of SPR720, Spero's investigational oral antimicrobial agent being evaluated in patients with nontuberculous mycobacterial pulmonary disease (NTM-PD).
- 02/05/2021
|
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- CAMBRIDGE, Mass., Jan. 29, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that on January 29, 2021 the Compensation Committee of Spero's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 74,300 shares of its common stock to six new employees under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, or the 2019 Inducement Plan. The stock options were granted as inducements material to the new employees becoming employees of Spero in accordance with Nasdaq Listing Rule 5635(c)(4).
- 01/29/2021
|
Spero Therapeutics (SPRO) Sees Hammer Chart Pattern: Time to Buy?
- Spero Therapeutics (SPRO) has been struggling lately, but the selling pressure may be coming to an end soon.
- 01/26/2021
|
Spero Therapeutics Announces Issuance of Allowance for a U.S. Patent Covering Lead Candidate Tebipenem HBr
- CAMBRIDGE, Mass., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,889,587, which is directed to a crystalline formulation of tebipenem HBr, Spero's oral carbapenem in development for the treatment of complicated urinary tract infection (cUTI) and acute pyelonephritis (AP). In September 2020, Spero announced positive top-line results from its Phase 3 ADAPT-PO clinical trial of tebipenem HBr in cUTI and AP.
- 01/21/2021
|
Spero: Tebipenem HBr's H2 2021 NDA, SPR720's Phase 2a Data Release And More
- Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for high unmet need areas involving multi-drug-resistant bacterial infections and rare diseases. Spero is running three clinical phase therapeutic programs including Tebipenem HBr - Phase 3 [complete] for cUTIs, SPR720 - Phase 2a for NMT-PD, and SPR206 - Phase 1 for MDRi.
- 01/13/2021
|
Spero Therapeutics Announces Appointment of Sath Shukla as Chief Financial Officer
- CAMBRIDGE, Mass., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced the appointment of Satyavrat “Sath” Shukla, CFA, as Chief Financial Officer, effective as of January 4, 2021.
- 12/17/2020
|
Spero Therapeutics Added to the NASDAQ Biotechnology Index
- CAMBRIDGE, Mass., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 21, 2020.
- 12/16/2020
|
Spero Therapeutics Announces First Patient Dosed with SPR720 in Phase 2a Clinical Trial in Patients with Nontuberculous Mycobacterial Pulmonary Disease
- CAMBRIDGE, Mass., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections, today announced that it has initiated dosing in patients with nontuberculous mycobacterial pulmonary disease (NTM-PD) in its dose-ranging Phase 2a clinical trial of SPR720, Spero's oral antimicrobial agent in development for the treatment of NTM-PD.
- 12/10/2020
|
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- CAMBRIDGE, Mass., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that on November 30, 2020 the Compensation Committee of Spero's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 76,200 shares of its common stock to ten new employees under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, or the 2019 Inducement Plan. The stock options were granted as inducements material to the new employees becoming employees of Spero in accordance with Nasdaq Listing Rule 5635(c)(4).
- 11/30/2020
|
Spero Therapeutics to Present at the Evercore ISI HealthCONx Conference on December 3, 2020
- CAMBRIDGE, Mass., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will participate in a fireside chat at the 3rd Annual Evercore ISI HealthCONx Conference taking place December 1 – 3, 2020.
- 11/30/2020
|
Spero Therapeutics' (SPRO) CEO Ankit Mahadevia on Q3 2020 Results - Earnings Call Transcript
- Spero Therapeutics' (SPRO) CEO Ankit Mahadevia on Q3 2020 Results - Earnings Call Transcript
- 11/07/2020
|
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- CAMBRIDGE, Mass., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that on October 30, 2020 the Compensation Committee of Spero's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 30,000 shares of its common stock to three new employees under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, or the 2019 Inducement Plan. The stock options were granted as inducements material to the new employees becoming employees of Spero in accordance with Nasdaq Listing Rule 5635(c)(4).
- 11/03/2020
|
5 Healthcare Stocks the Experts at Aquilo Capital Management Are Buying (1 Has Gained 88% This Month)
- Marc Schneidman's Aquilo Capital Management is a San Francisco-based, healthcare-focused long/short hedge fund that was founded in 2010. The fund uses CIO Schneidman's 20 years of industry expertise in biotech research and investments, which included 15 years working at Mark Lampert's Biotechnology Value Fund, to seek out mispriced small-cap companies in the biotech sector. The fund's assets under management surpassed $500 million as of August 2020.
- 10/26/2020
|
